# Diagnostic Accuracy of Adenosine Deaminase and Lymphocyte Proportion in Pleural Fluid for Tuberculous Pleurisy in Different Prevalence Scenarios

**Alberto García-Zamalloa**¹, **Jorge Taboada-Gomez**²

1 Mycobacterial Infection Study Group (GEIM) from the Spanish Infectious Diseases Society, Department of Internal Medicine, Mendaro Hospital, Mendaro, Gipuzkoa, Spain, 2 Preventive Medicine and Western Gipuzkoa Clinical Research Unit, Mendaro Hospital, Mendaro, Gipuzkoa, Spain

---

## Abstract

**Background:** Tuberculous pleural effusion (TPE) is a paucibacillary manifestation of tuberculosis, so isolation of *Mycobacterium tuberculosis* is difficult, biomarkers being an alternative for diagnosis. Adenosine deaminase (ADA) is the most cost-effective pleural fluid marker and is routinely used in high prevalence settings, whereas its value is questioned in areas with low prevalence. The lymphocyte proportion (LP) is known to increase the specificity of ADA for this diagnosis. We analyse the diagnostic usefulness of ADA alone and the combination of ADA ≥40 U/I (ADA₄₀) and LP≥50% (LP₅₀) in three different prevalence scenarios over 11 years in our area.

**Materials and Methods:** Biochemistry, cytology and microbiology studies from 472 consecutive pleural fluid samples were retrospectively analyzed. ADA and differential cell count were determined in all samples. We established three different prevalence periods, based on percentage of pleural effusion cases diagnosed as tuberculosis: 1998–2000 (31.3%), 2001–2004 (11.8%), and 2005–2008 (7.4%). ROC curves, dispersion diagrams and pre/post-test probability graphs were produced. TPE accounted for 73 episodes (mean prevalence: 15.5%). The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for ADA₄₀ were 89%, 92.7%, 69.2% and 97.9%, respectively. For ADA₄₀+LP₅₀ the specificity and PPV increased (98.3% and 90%) with hardly any decrease in the sensitivity or NPV (86.3% and 97.5%). No relevant differences were observed between the three study periods.

**Conclusions/Significance:** ADA remains useful for the diagnosis of TPE even in low-to-intermediate prevalence scenarios when combined with the lymphocyte proportion.

---

## Introduction

Tuberculous pleural effusion (TPE) is a common manifestation of extrapulmonary tuberculosis, and is the leading cause of pleural effusion in developing world regions, while it is much less common in developed countries [1–3]. The diagnosis of TPE depends on the demonstration of tubercle bacilli in pleural fluid, a pleural biopsy specimen or sputum, or the demonstration of granulomas in the pleura [4]. Due to the paucity of *Mycobacterium tuberculosis* in the pleural fluid, the performance of a pleural biopsy has historically been considered the most reliable method to confirm the diagnosis when tuberculous aetiology of a pleural effusion is suspected. However, since pleural tissue sampling is more difficult than simple thoracocentesis, pleural fluid markers of TPE have been extensively evaluated as an attractive alternative to pleural biopsy [5]. ADA is the most cost-effective pleural fluid marker and is routinely employed as a screening tool, in particular, in countries where tuberculosis is endemic [1].

Theoretically, according to Bayes theorem, the predictive value of a marker such as ADA depends not only on its sensitivity and specificity, but also on the local prevalence of the disease: in a high prevalence setting the positive predictive value (PPV) of elevated ADA would increase, while in a low prevalence setting the PPV would decline but the negative predictive value (NPV) would remain high, so a low concentration of ADA might rule out TPE [1,5]. On the other hand, the combination of ADA and the pleural fluid lymphocyte proportion (LP) has come to be recognised as an excellent approach for increasing the specificity of ADA test [6].

The aim of this research was to assess the accuracy of ADA combined with pleural fluid LP for TPE in our area, in three different prevalence settings over a total period of eleven years.

## Methods

We retrospectively reviewed all consecutive patients with pleural effusion who underwent a diagnostic thoracocentesis at Mendaro Hospital (community hospital, which provides healthcare to Bajo Deba Area - 80,000 inhabitants - in Basque Country, Spain) from...
January 1998 to December 2008. The ADA level and LP in pleural fluid had been determined in all samples. We recorded demographic and clinical data (body temperature on admission, and presence of cough, chest pain and/or dyspnoea), and pleural fluid data (total and differential cell count, protein, lactate dehydrogenase-LDH, pH, glucose, ADA, cytology, aerobic and anaerobic culture, Lowenstein-Jensen and MGIT–Bactec culture), along with serum glucose, protein and LDH. Histopathological and microbiological findings in pleural biopsy specimens, final diagnosis and, in TPE cases, first and last day of treatment and the combination of anti-tuberculosis drugs given were also recorded. When more than one thoracocentesis was performed, the statistical analysis was performed using only the data from the first pleural fluid sample, although the outcomes of every sample were recorded.

Regarding the diagnostic criteria, two subclasses of TPE were identified: 1) confirmed pleural tuberculosis (CPTE): identification of the bacillus in pleural fluid, sputum or pleural biopsy by stain or by culture; or by the presence of granulomatous inflammation on pleural biopsy, and 2) probable pleural tuberculosis (PTPE): clinical and radiological evidence for tuberculosis in the absence of any other obvious cause associated with pleural effusion and positive response to a complete course of anti-tuberculosis treatment, confirmed through outpatient follow-up of at least twelve months. Malignant effusion was diagnosed when malignant cells were found in pleural fluid or pleural biopsy. Uncomplicated parapneumonic effusion (UPE) referred to any exudative effusion associated with bacterial pneumonia, lung abscess or bronchietasis which resolved with antibiotics alone, while patients with pH <7.20 or glucose <40 mg/dl or Gram's stain or culture positive were classed as having complicated parapneumonic effusion (CPE), with empyema describing the presence of frank pus in the pleural cavity [7]. Within the miscellaneous group of diagnoses we included other types of pleural effusion with different aetiologies and defined by well established clinical criteria. Transudative effusions were defined following Light's criteria [8]. Finally, there was a last group for patients with pleural effusion in whom an exact diagnosis had not been reached.

For the purposes of this study, following the approach of previous authors, “prevalence” was used to refer to the number of cases of a given type of pleural effusion divided by the total number of pleural effusions studied, more appropriately named “pre-test probability” [1,5,9].

Pleural fluid ADA levels were determined by using an automated ultraviolet kinetic assay (Roche Diagnostics, Mannheim, Germany). White blood cells were manually counted in a Thoma chamber, and differential cell counts in pleural fluid were performed after Wright’s staining by counting, whenever possible, 200 cells. The LP was calculated as the number of lymphocytes divided by the total number of white cells.

Statistical analysis was performed using SPSS 18.0 statistical software. Categorical variables were analyzed with the χ² test and continuous variables were compared using the Student’s t-test. In addition, whenever parametric tests could not be used, Kruskal-Wallis one-way analysis of variance was performed to compare group means. Assessing the performance with the ROC curve, we explored the usefulness of a single parameter relating the ADA levels to the proportion of lymphocytes; specifically, we multiplied the level of ADA by the LP, calling the resulting new variable ADA-LP. Diagnostic accuracy, including 95% confidence intervals, assessed using sensitivity, specificity, predictive values, likelihood ratios and area under the ROC curve (AUC) in the tuberculosis and non-tuberculosis sub-groups. ROC curves were constructed to compare ADA with ADA-LP. Whenever appropriate, Pearson’s correlation coefficient was also calculated.

This research counts with the permission of the CEO of the Mendaro Hospital and the approval of the Western Gipuzkoa Research Commission for the development of the study.

Results

A total of 472 episodes of pleural effusion were analysed, with a male:female ratio of 294:178 cases (62.3%;37.7%). Mean age was 66.2 years (SD of 20.25 years).

Overall, there were 73 cases of TPE (15.4%), 29 of CPE or empyema (6.1%), 92 of UPE (19.5%), 105 of malignant effusion (22.2%), 78 of miscellaneous exudates (16.5%), 61 of transudative effusion (12.9%) and 34 of undiagnosed pleural effusion (7.2%).

Among the 73 episodes of TPE, 25 cases were confirmed to be pleural tuberculosis (CTPE) (19 by positive culture and 6 by presence of granulomas in pleural biopsy tissue) and the remaining 48 cases were probable pleural tuberculosis (PTPE), given the clinical symptoms combined with biochemical and cytological results from pleural fluid and response to a complete course of treatment.

ADA activity was significantly higher in CTPE, PTPE and CPE/empyema (Table 1). Specifically, using the Kruskal-Wallis one-way analysis of variance, we found statistically significant differences in mean ADA levels between the CTPE, PTPE and CPE/empyema group and the other diagnostic entities: UPE, malignant effusions, miscellaneous exudates, transudative and undiagnosed effusions. Differences between tuberculosis (confirmed or probable) and CPE/empyema were not significant. Nevertheless, CTPE and PTPE were easily distinguished from CPE/empyema by the pleural fluid white cell count: mean LP in TPE and CPE/empyema being 83.3% and 16%, respectively. In Table 2 we report the number and percentage of positive results obtained for the two diagnostic criteria used: an ADA level equal to or greater than 40 U/l (ADA40) and a LP equal to or greater than 50% (LP50), by type of pleural effusion. Although in six out of the 25 patients with CTPE, the ADA level was lower than 40 U/l in the first pleural fluid sample, a subsequent thoracocentesis yielded an ADA level higher than 40 U/l in four cases.

Over the whole period 1998–2008 (mean prevalence of 15.5%), the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for ADA40 were 89.0%, 92.7%, 69.2% and 97.9% (Table 3). The addition of LP50 to ADA40 increased the specificity of the latter for the diagnosis of TPE to 98.3%, and its PPV to 90% (Table 4).

For ADA40+LP50, sensitivity, specificity, PPV and NPV respectively were 87.8%, 100%, 100% and 94.7% for the first period (1998–2000, prevalence: 31.3%); 83.3%, 99.3%, 93.8% and 97.8% for the second period (2001–2004, prevalence: 11.8%); and 85.7%, 99.3%, 93.8% and 98.3% for the third period (2004–2008, prevalence: 7.4%).

For the whole period, the area under the ROC curve for ADA levels was 0.939 (95% CI 0.908–0.969) versus 0.973 (95% CI: 0.949–0.997) for ADA-LP (Figure 1), with no statistically significant differences between the three periods.

Notably, all malignant effusions developed in patients over 39 years old, and just four cases out of the 105 showed an ADA level over 40 U/l, only two of them being found to be lymphocytic (1.9%). TPE, in contrast, predominated in younger people and even linear regression analysis showed that ADA activity decreased slightly with the age of the patients affected by TPE (Pearson’s correlation coefficient of –0.074). The ADA levels of 43 out of 73 patients with TPE were within the range of 40–70 U/l (Figure 2).
We observed that six out of 75 (8%) cases of lymphocytic pleural effusion had ADA >40 U/l and were of nontuberculous origin: three empyemas and one UPE (all of them after admission and drainage in another centres), along with two malignant effusions. Further, amongst the cases of CPE/empyema, 20 out of 29 (69%) were found to have an ADA level over 40 U/l, and all of them (except for the three aforementioned cases) were neutrophilic.

**Discussion**

Due to the Bayesian interpretation of the well established performance of ADA for the diagnosis of TPE, it has acquired popularity as an excellent tool above all in areas of high incidence of tuberculosis [10]. Nevertheless, the role of ADA in low-intermediate prevalence settings remained uncertain, so our study comes to demonstrate that combining ADA and LP in pleural fluid the specificity and PPV of the former increase substantially, especially in low-to-intermediate prevalence settings, making this test a suitable diagnostic tool in such scenarios.

The definitive diagnosis of TPE depends on the demonstration of *Mycobacterium tuberculosis* in pleural fluid, sputum or pleural biopsy specimen, and can also be established with reasonable certainty by demonstration of granuloma in the parietal pleura. Microscopy of the pleural fluid for acid fast bacilli is positive in about 55%. Thoracoscopy, pleural biopsy to that of the pleural fluid increases the overall microbiological yield from 35% to 55%, and in some authors’ opinion this invasive practise may be not justified in order to obtain such a diminished advantage [11].

Along with these biomarkers, nucleic acid amplification (NAA) tests enable direct detection of *Mycobacterium tuberculosis* in clinical specimens such as pleural fluid within hours of their collection, and can also provide information regarding antimicrobial resistance [1,11]. However, although commercial tests were found to have a reasonably high specificity of 98% in a systematic review and meta-analysis of 40 studies, they had a low and variable sensitivity of 62% (95% CI: 43–77%) for diagnosing TPE [15]. Due to the individual limitations of each test, even sophisticated and expensive combinations of ADA, IFN-γ and NAA tests have been proposed [16].

Adenosine deaminase (ADA) is an essential enzyme in the metabolism of purine nucleosides. There are two main isoenzymes of ADA: ADA1 and ADA2. ADA 1 is ubiquitous, whereas ADA2 has been found only in monocytes and macrophages. Most of the ADA in pleural tuberculosis is ADA2 [17]; although better than total ADA for diagnosing pleural tuberculosis [18], the separation of ADA into its isoenzymes is more expensive than the basic ADA test, not readily available and its use is so far limited [1,5,11,19]. The most widely accepted cut-off level of ADA for the diagnosis of TPE is 40 U/l [1,12,20], and an LP≥50% is conventionally accepted as a practical cut-off for lymphocytic effusion [21]. Moreover, ADA ≥70 U/l (when lymphocyte-to-neutrophil ratio is ≥0.75) has also been proposed as virtual diagnosis of TPE [11].

High ADA levels in lymphocytic pleural effusions have also been reported in rheumatoid arthritis, lymphoma, bronchoalveolar carcinoma, mesothelioma, systemic lupus erythematosus, mycosis, and chlamydia pneumonia, psittacosis, paragonimiasis, infectious mononucleosis, brucellosis, familial Mediterranean fever, histoplasmosis and coccidiodomycosis [22]. However, apart from tuberculosis, the main disease that causes an elevated ADA is parapneumonic pleural effusion: one-third of cases of UPE and two-thirds of those of CPE/empyema may have a high ADA level, but both conditions are easily distinguished from TPE because they develop neutrophilic effusions [1,5]. Moreover, several studies with patients suffering from nontuberculous lymphocytic pleural effusions have reported ADA levels over the diagnostic cut-off of 40 U/l in less than 3% of cases [23,24].

**Table 1.** ADA levels by type of pleural effusion in three tuberculosis pleural effusion prevalence periods (1998–2000, prevalence: 31.3%; 2001–2004, prevalence: 11.8%; and 2005–2008, prevalence: 7.4%).

|                | Whole period | 1998–2000 | 2001–2004 | 2005–2008 |
|----------------|-------------|-----------|-----------|-----------|
|                | Mean        | Standard Deviation | Mean        | Standard Deviation | Mean        | Standard Deviation |
| CPE            | 64.2        | 16.2       | 63.1       | 16.0       | 66.2       | 21.6       | 65.3       | 11.3       |
| Malignant      | 21.4        | 23.7       | 14.9       | 8.5        | 16.9       | 11.3       | 28.8       | 33.4       |
| Miscellaneous  | 19.5        | 18.9       | 20.6       | 41.6       | 17.6       | 8.2        | 20.8       | 6.3        |
| Undiagnosed    | 19.0        | 8.5        | 12.6       | 3.8        | 18.5       | 8.2        | 25.2       | 7.6        |
| Total          | 28.4        | 26.9       | 31.2       | 32.4       | 24.7       | 22.9       | 29.4       | 25.4       |

CTPE: confirmed pleural tuberculosis; PTPE: probable pleural tuberculosis; CPE: complicated parapneumonic effusion; UPE: uncomplicated parapneumonic effusion.

doi:10.1371/journal.pone.0038729.t001
| Type of pleural effusion | Whole period (1998–2008) | 1998–2000 | 2001–2004 | 2005–2008 |
|--------------------------|--------------------------|-----------|-----------|-----------|
|                          | ADA ≥40 U/L               | ADA ≥40 U/L + Lymphocytes ≥50% | ADA ≥40 U/L + Lymphocytes ≥50% | ADA ≥40 U/L + Lymphocytes ≥50% | ADA ≥40 U/L + Lymphocytes ≥50% |
| CTPE                     | 19/25 76.00 (%)           | 18/25 72.00 (%)            | 11/13 84.62 (%)          | 5/8 62.50 (%)         | 3/4 75.00 (%)             |
| PTPE                     | 46/48 95.83 (%)           | 45/48 93.75 (%)            | 26/28 92.86 (%)          | 10/10 100.00 (%)     | 10/10 100.00 (%)          |
| CPE                      | 20/29 68.97 (%)           | 3/29 10.34 (%)             | 0/5 0.00 (%)             | 5/8 62.50 (%)         | 0/8 0.00 (%)              |
| UPE                      | 3/92 3.26 (%)             | 1/92 1.09 (%)              | 0/16 0.00 (%)            | 1/31 3.23 (%)        | 0/31 0.00 (%)             |
| Malignant                | 4/105 3.81 (%)            | 2/105 1.90 (%)             | 0/24 0.00 (%)            | 1/37 2.70 (%)        | 1/37 2.70 (%)             |
| Miscellaneous            | 1/78 1.28 (%)             | 0/78 0.00 (%)              | 1/15 6.67 (%)            | 0/31 0.00 (%)        | 0/31 0.00 (%)             |
| Transudative             | 0/61 0.00 (%)             | 0/61 0.00 (%)              | 0/19 0.00 (%)            | 0/16 0.00 (%)        | 0/16 0.00 (%)             |
| Undiagnosed              | 1/34 2.94 (%)             | 1/34 2.94 (%)              | 0/11 0.00 (%)            | 0/11 0.00 (%)        | 0/11 0.00 (%)             |
| Total                    | 94/472 19.92 (%)          | 70/472 14.83 (%)           | 41/131 31.30 (%)         | 36/131 27.48 (%)     | 31/189 16.40 (%)          |

CTPE: confirmed pleural tuberculosis; PTPE: probable pleural tuberculosis; CPE: complicated parapneumonic effusion; UPE: uncomplicated parapneumonic effusion. 
doi:10.1371/journal.pone.0038729.t002
Three major meta-analyses, based on 75 studies including a total of 14,505 patients, have been performed over the last decade, and these have demonstrated a uniformly high diagnostic performance of pleural ADA for TPE [12,20,25]. One of the major concerns regarding the sensitivity of ADA was its reliability in immunocompromised patients; however, more recent studies have demonstrated that ADA is a reliable marker of tuberculous pleurisy in HIV-positive patients, even in those with a low CD4 T-cell count [26,27]. On the other hand, ADA levels in pleural fluid are also elevated in renal transplant recipients with tuberculous pleurisy [5].

In 1998, Valdés et al. were the first to propose obviating pleural biopsy for the diagnosis of tuberculous pleuritis in patients younger than 35 years of age, in areas with an intermediate [say 25%] or high prevalence of tuberculosis [28]. The limitation to young patients was related to concerning the more common development of malignant effusions in older patients [29] and this approach was theoretically more suitable in intermediate-to-high prevalence areas according to the Bayesian interpretation of the predictive value of ADA.

To date, almost all the studies performed concerning the diagnostic value of ADA for TPE were reported from intermediate-to-high prevalence areas, so acceptance of this test was not universal and remained contentious in countries with lower prevalence. Given this, it was considered desirable that further studies be carried out in areas of low TPE prevalence in order to confirm the suitability of this biomarker in these areas [30].

Within the Multicenter Project on Tuberculosis Research performed in Spain from June 1996 to May 1997, the Bajo Deba Area was found to have the highest incidence of tuberculosis in the Basque Country (83 cases per 100,000 individuals) [31]. Subsequent implementation of a Tuberculosis Control Program by the Basque Health Service led to sustained epidemiological improvement. In the first period (1998–2000), with a 31% (intermediate-to-high) TPE prevalence scenario, we obtained a sensitivity, specificity, PPV and NPV of ADA40 for the diagnosis of TPE of 90.2%, 95.6%, 90.2% and 95.6%, close to values reported from interme-

diate-to-high prevalence areas according to the Bayesian interpretation of the test probability plots. Specifically, for rates of pleural TPE prevalence of 5%, 25% and 85% (estimated rates for low, intermediate and high prevalence countries [12]), post-test probabilities for an ADA40 value of 41%, 81% and 99% respectively; whereas for ADA40+LP50 they were 78%, 95% and 99% respectively (Figure 4).

Regarding the comparative study of TPE and malignant pleural effusions (Figure 2), there are some interesting findings to comment on: 1) all patients with malignant effusion in our series were over 39 years of age, and almost all of them had an ADA level <40 U/l; and 2) TPE predominated in younger patients, with a linear regression analysis demonstrating that ADA activity decreased with age among the patients with TPE, as previously reported by other authors [33]. Further, 43 out of 73 (59%) patients diagnosed with TPE showed an ADA level in pleural fluid of between 40 and 70 U/l. Finally, only two out of 105 patients (1.9%) with malignant pleural effusion had an ADA level and LP50 comparable to those theoretically attributable to TPE, so, as reported by other authors [23,24], although always a concern, a high ADA level in nontuberculous lymphocytic pleural effusions (including malignant ones) is relatively uncommon.

Our study does have limitations: in particular, being retrospective, diagnoses based on clinical evidence were included, and though this is not optimal it is considered acceptable [16]. We note that the administration of empirical anti-tuberculosis treatment to patients with lymphocytic exudates and a high ADA level in pleural fluid when there is clinical suspicion of tuberculosis is a common practice in intermediate-to-high burden settings like our country [10]. Moreover, the universal determination of ADA level in all pleural fluid samples taken, the absence of significant differences between its mean level in the two diagnostic groups (confirmed and probable pleural tuberculosis), and the follow-up of all the patients diagnosed with TPE until complete recovery under anti-tuberculosis treatment are positive features, enhancing the validity of our study.

### Table 3. Bayesian probabilities of test parameters used. ADA ≥40 U/L

| Whole period | 1998–2000 | 2001–2004 | 2005–2008 |
|--------------|-----------|-----------|-----------|
| Prevalence   | 15.5      | 31.3      | 11.8      | 7.4  |
| Sensitivity  | 89.0      | 90.2      | 83.3      | 92.9 |
| Specificity  | 92.7      | 95.6      | 94.8      | 89.7 |
| Positive Predictive Value | 69.2 | 90.2 | 68.2 | 41.9 |
| Negative Predictive Value | 97.9 | 95.6 | 97.7 | 99.4 |
| Positive Likelihood Ratio | 12.3 | 20.3 | 16.0 | 9.0 |
| Negative Likelihood Ratio | 0.1 | 0.1 | 0.2 | 0.1 |

### Table 4. Bayesian probabilities of test parameters used. ADA ≥40 U/L and Lymphocytes ≥50%

| Whole period | 1998–2000 | 2001–2004 | 2005–2008 |
|--------------|-----------|-----------|-----------|
| Prevalence   | 15.5      | 31.3      | 11.8      | 7.4  |
| Sensitivity  | 86.3      | 87.8      | 83.3      | 85.7 |
| Specificity  | 98.3      | 100       | 99.3      | 96.6 |
| Positive Predictive Value | 90.0 | 100 | 93.8 | 66.7 |
| Negative Predictive Value | 97.5 | 94.7 | 97.8 | 98.8 |
| Positive Likelihood Ratio | 49.2 | - | 111.7 | 25.0 |
| Negative Likelihood Ratio | 0.1 | 0.1 | 0.2 | 0.2 |

doi:10.1371/journal.pone.0038729.t003
doi:10.1371/journal.pone.0038729.t004
Figure 1. ROC curve.
doi:10.1371/journal.pone.0038729.g001

Figure 2. Cases of tuberculosis pleural effusion (TPE) and malignant effusion as a function of age.
doi:10.1371/journal.pone.0038729.g002
In conclusion, local prevalence of TPE has a more limited impact than expected (by Bayesian interpretation) on the diagnostic value of ADA when combined with LP, remaining a useful diagnostic tool in low-to-intermediate prevalence scenarios. In our experience, ADA $\geq 40$ U/l is a highly suitable cut-off level, and in patients younger than 40 years it might
constitute a virtual diagnosis of TPE when effusions are lymphocytic.

Acknowledgments

We would like to express our gratitude to Professor Emilio Perez-Trallero M.D. for his invaluable suggestions, opinions and changes after expert revision of our manuscript.

References

1. Porcel JM (2009) Tuberculous pleural effusion. Lung 187: 263–270.
2. Udwadia ZF, Sen T (2010) Pleural tuberculosis: an update. Curr Opin Pulm Med 16: 399–406.
3. Baumann MH, Nolan R, Petrimi M, Gary Lee YC, Light RW, et al (2007) Pleural tuberculosis in the United States: incidence and drug resistance. Chest 131: 1125–1132.
4. Light RW (2001) Pleural diseases. Baltimore: Lippincott, Williams and Wilkins. pp: 162–195.
5. Krenke R, Korczynski P (2010) Use of pleural fluid levels of adenosine deaminase and interferon gamma in the diagnosis of tuberculosis pleuritis. Curr Opin Pulm Med 16: 367–375.
6. Burgess LJ, Maritz FJ, Le Roux I, Taljaard JJF (1996) Combined use of pleural adenosine deaminase with lymphocyte/neutrophil ratio: increased specificity for the diagnosis of tuberculous pleurisy. Chest 109: 414–419.
7. Light RW (2001) Pleural diseases. Baltimore: Lippincott, Williams and Wilkins. pp 151–181.
8. Light RW (2001) Pleural diseases. Baltimore: Lippincott, Williams and Wilkins. pp 96–107.
9. Valdés L, Álvarez D, San José ME, Juanatey JR, Pose A, et al (1995) Value of Adenosine Deaminase in the diagnosis of pleural tuberculosis in young patients in a region with high prevalence of tuberculosis. Thorax 50: 600–603.
10. Porcel JM, Esquerra A, Biba S (2010) Diagnostic performance of adenosine deaminase activity in pleural fluid: a single-center experience with over 2100 consecutive patients. Eur J Intern Med 21: 419–423.
11. Light RW (2010) Update on tuberculous pleural effusion. Respiratory 15: 451–458.
12. Greco S, Girardi E, Masciangelo R, Capocotta GR, Saltini C (2003) Adenosine Deaminase and interferon gamma measurements for the diagnosis of pleural tuberculosis: a meta-analysis. Int J Tuberc Lung Dis 7 (8): 777–786.
13. Jiang J, Shi HZ, Liang QL, Qin SM, Qin XJ (2007) Diagnostic value of Interferon-γ in tuberculous pleurisy. A metaanalysis. Chest 131: 1133–1141.
14. Sharma SK, Banga A (2005) Pleural fluid Interferon-γ and Adenosine Deaminase levels in tuberculosis pleural effusion: a cost-effective analysis. J Clin Lab Anal 19: 40–46.
15. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM Jr (2004) Nucleic acid amplification tests in the diagnosis of tuberculosis pleuritis: a systematic review and meta-analysis. BMC Infect Dis 4:6.
16. Villagómez MV, Labrada LA, Saracía NG (2000) Evaluation of Polymerase Chain Reaction, Adenosine Deaminase, and Interferon-γ in pleural fluid for the differential diagnosis of pleural tuberculosis. Chest 118: 1355–1364.
17. Pérez-Rodríguez E, Jimenez Castro D (2000) The use of adenosine deaminase and adenosine deaminase enzymes in the diagnosis of tuberculous pleuritis. Curr Opin Pulm Med 6: 259–266.
18. Valdés L, San José E, Alvarez D, Valle JM (1996) Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy. Eur Respir J 9: 747–751.
19. Zermolin AE, Burgess LJ, Castens ME (2009) The diagnostic utility of adenosine deaminase isoenzymes in tuberculous pleural effusions. Int J Tuberc Lung Dis 13 (2): 214–220.
20. Liang QL, Shi HZ, Wang K, Qin SM, Qin XJ (2000) Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis. Respir Med 102: 744–754.
21. Hooper C, Gary Lee YC, Maskell N, on behalf of the BTS Pleural Guideline Group (2010) Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010. Thorax 65 (Suppl 2): i4–i17.
22. Gopi A, Madhavan SM, Sharma SK, Shan SA (2007) Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest 131: 880–889.
23. Gary Lee YC, Rogers JT, Rodriguez RM, Miller KD, Light RW (2001) Adenosine deaminase levels in nontuberculous lymphocytic pleural effusions. Chest 120: 356–361.
24. Jimenez Castro D, Diaz Nuevo G, Perez-Rodriguez E, Light RW (2003) Diagnostic value of adenosine deaminase in nontuberculous lymphocytic pleural effusions. Eur Respir J 21: 229–224.
25. Morisson P, Neves DD (2008) Evaluation of adenosine deaminase in the diagnosis of pleural tuberculosis: a Brazilian meta-analysis. J Bras Pneumol 34 (4): 217–224.
26. Riamtawon P, Chaowalit P, Wongpaengmi P (1999) Diagnostic value of pleural fluid adenosine deaminase in tuberculous pleuritis with reference to HIV coinfection and a Bayesian analysis. Chest 116: 97–103.
27. Baba K, Hoosen AA, Langhans N, Dyrholm-Riise A, Långman TB, et al (2003) Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. PLoS ONE 3 (7): e2738.
28. Valdés L, Álvarez D, San José E, Panela P, Valle JM, et al (1998) Tuberculous pleurisy: a study of 254 patients. Arch Intern Med 158: 2017–2021.
29. Valdés L, Álvarez D, Valle JM, Posé A, San José E (1996) The etiology of pleural effusions in an area with high incidence of tuberculosis. Chest 109: 158–162.
30. McGrath EE, Anderson PB (2010) Diagnostic tests for tuberculous pleural effusion. Eur J Clin Microbiol Infect Dis 29: 1187–1193.
31. García-Zamalía AM, Arrizabalaga J (2008) Tuberculosis in the Bajo Deba area (Guipuzcoa, Spain) from 1995 to 2006. Enferm Infec Med 24 (4): 259–263.
32. Diacon AH, Van de Wal, Wyser C, Smedema JP, Bezuidenhout J, et al. (2003) Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J 22(4): 589–591.
33. Zaric B, Kuruc V, Milovancev A, Markovic M, Sarcev T, et al (2008) Differential diagnosis of tuberculous and malignant pleural effusions: what is the role of Adenosine Deaminase? Lung 186(3): 233–240.